Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 4.923
Filtrar
1.
J Public Health Manag Pract ; 30(3): 411-415, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38603747

RESUMO

During the COVID-19 vaccine rollout, local public health agencies were responsible for vaccinating a wide variety of communities. Dakota County Public Health (Dakota County, Minnesota) implemented a program that offered COVID-19 vaccines in a variety of settings, such as county public health buildings, community sites, in-home, mass vaccination clinics, and a mobile clinic unit. The purpose of this analysis is to compare the demographics of vaccinations administered at Dakota County COVID-19 vaccination clinics based on clinic site. More than half (52.5%) of vaccinations administered at mobile clinic sites were administered to Hispanic or Latino clients, while at the mass vaccination clinic site, 5.4% of vaccinations were administered to Hispanic or Latino clients. In addition, 59.6% of in-home vaccinations were administered to adults 65 years and older. Offering COVID-19 vaccination clinics in a variety of clinic settings strategically throughout the community helped increase vaccine reach to diverse communities.


Assuntos
COVID-19 , Vacinas contra Influenza , Adulto , Humanos , Vacinas contra COVID-19/uso terapêutico , Vacinação em Massa , Saúde Pública , Unidades Móveis de Saúde , COVID-19/epidemiologia , COVID-19/prevenção & controle , Vacinação
2.
Sci Rep ; 14(1): 8009, 2024 04 05.
Artigo em Inglês | MEDLINE | ID: mdl-38580716

RESUMO

Understanding the factors that influence people's decisions regarding vaccination is essential to promote vaccination. We aimed to clarify the motivations for receiving booster vaccines. We conducted a paper-based questionnaire distributed during January-February 2022 involving students and faculty staff who received the first COVID-19 vaccination at the mass vaccination program during June-September 2021 at Keio University. A total of 1725 participants were enrolled, and all completed the survey. Among these, 64.9% reported a significant adverse event (AEs) affecting daily life after the second vaccine. "Fear of severe COVID-19 illness" (72.6%) was the most common reason for getting vaccinated, followed by "concern of infecting others" (68.4%) and "fear of COVID-19 infection itself" (68.3%). Television emerged as the most influential source of information (80%), followed by university information (50.2%) and social networking sites (42.8%). Multivariate analysis revealed "fear of severe COVID-19 illness", "fear of COVID-19 infection itself", and "trust in the efficacy and safety of the vaccines in general" were significantly correlated with willingness to receive paid vaccinations. The severity of AEs and source of information were not related to participants' willingness to receive booster vaccinations. Participants with positive reasons for vaccination were more likely to accept a third dose.


Assuntos
Vacinas contra COVID-19 , COVID-19 , Humanos , Vacinas contra COVID-19/efeitos adversos , COVID-19/prevenção & controle , Motivação , Estudos Transversais , Japão/epidemiologia , Universidades , Vacinação em Massa , Estudantes , Vacinação
3.
BMC Public Health ; 24(1): 866, 2024 Mar 20.
Artigo em Inglês | MEDLINE | ID: mdl-38509496

RESUMO

BACKGROUND: Hepatitis B virus (HBV) is associated with several acute and long-term complications and vaccination is the cornerstone of prevention. A recent outbreak in Gulu, Uganda, one of the districts covered by a mass vaccination campaign, suggests low uptake of HBV vaccination. This study aims to determine the uptake and completion of HBV vaccination and associated factors among residents of Gulu, Uganda. METHODS: A mixed methods cross-sectional study was conducted in Gulu, Northern Uganda, among 434 adult residents. A pretested questionnaire was used to collect data on socio-demographics, perceptions, and knowledge of HBV vaccination. Modified Poisson regression analysis was used in STATA 14 software to obtain prevalence ratios for the association between the independent and dependent variables. For qualitative data, 9 key informant interviews were conducted and thematic analysis was done using Quirkos software. RESULTS: Out of the 434 respondents, 41.9% had received at least one dose of the hepatitis B vaccine, 32.5% had received at least 2 doses, and only 20% had completed all 3 doses, with an overall completion rate of 47.8% for participants who had been initiated on the vaccine. Gender, residence, risk perception of Hepatitis B infection, perceived safety of the vaccine, and awareness of mass vaccination were associated with uptake of Hepatitis B vaccination. Residence, knowledge, and perception of being at risk of acquiring Hepatitis B were associated with completion. Qualitative results revealed that the levels of uptake and completion could have been affected by access to vaccination sites; inadequate knowledge about the disease; myths about the vaccine and inadequate community engagement. CONCLUSION: Low Hepatitis B vaccine uptake and completion rates were observed in Gulu. To enhance vaccination coverage, future initiatives should prioritize awareness, education, and dispelling of vaccination myths. Additionally, increased government investment in training health workers can serve as a valuable strategy to improve information dissemination and awareness among the population.


Assuntos
Vacinas contra Hepatite B , Hepatite B , Adulto , Humanos , Estudos Transversais , Vacinação em Massa , Prevalência , Uganda/epidemiologia , Vacinação , Vírus da Hepatite B , Hepatite B/epidemiologia , Hepatite B/prevenção & controle
4.
Nature ; 627(8004): 612-619, 2024 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-38480877

RESUMO

Less than 30% of people in Africa received a dose of the COVID-19 vaccine even 18 months after vaccine development1. Here, motivated by the observation that residents of remote, rural areas of Sierra Leone faced severe access difficulties2, we conducted an intervention with last-mile delivery of doses and health professionals to the most inaccessible areas, along with community mobilization. A cluster randomized controlled trial in 150 communities showed that this intervention with mobile vaccination teams increased the immunization rate by about 26 percentage points within 48-72 h. Moreover, auxiliary populations visited our community vaccination points, which more than doubled the number of inoculations administered. The additional people vaccinated per intervention site translated to an implementation cost of US $33 per person vaccinated. Transportation to reach remote villages accounted for a large share of total intervention costs. Therefore, bundling multiple maternal and child health interventions in the same visit would further reduce costs per person treated. Current research on vaccine delivery maintains a large focus on individual behavioural issues such as hesitancy. Our study demonstrates that prioritizing mobile services to overcome access difficulties faced by remote populations in developing countries can generate increased returns in terms of uptake of health services3.


Assuntos
Vacinas contra COVID-19 , Serviços de Saúde Comunitária , Vacinação em Massa , Unidades Móveis de Saúde , Serviços de Saúde Rural , Cobertura Vacinal , Criança , Humanos , Serviços de Saúde Comunitária/métodos , Serviços de Saúde Comunitária/organização & administração , COVID-19/prevenção & controle , Vacinas contra COVID-19/administração & dosagem , Vacinas contra COVID-19/economia , Vacinas contra COVID-19/provisão & distribuição , Unidades Móveis de Saúde/organização & administração , Serviços de Saúde Rural/organização & administração , Serra Leoa , Meios de Transporte/economia , Cobertura Vacinal/economia , Cobertura Vacinal/métodos , Cobertura Vacinal/estatística & dados numéricos , Hesitação Vacinal , Vacinação em Massa/métodos , Vacinação em Massa/organização & administração , Feminino , Adulto , Mães
5.
Rev. esp. patol ; 57(1): 42-47, ene.-mar. 2024. ilus, tab
Artigo em Inglês | IBECS | ID: ibc-229921

RESUMO

Subsequent to mass vaccination programs against COVID-19, diverse side effects have been described, both at the injection site, such as pain, redness and swelling, and systemic effects such as fatigue, headache, muscle or joint pain. On rare occasions, a lymphadenopathic syndrome may develop, raising the clinical suspicion of a lymphoproliferative disorder. We present the case of a 30-year-old woman who developed self-limiting left axillary lymphadenopathy following COVID-19 vaccination. To date, only seven similar cases with a complete clinicopathological description have been published, and fourteen cases have been notified to the European adverse events databases (Eudravigilance) in relationship with vaccination against COVID-19. It is important to be aware of this potential complication when a lymphadenopathic syndrome develops following vaccination, to avoid unnecessary treatment. (AU)


Tras la vacunación masiva frente a la COVID-19 se han comenzado a describir diversos efectos adversos incluyendo efectos locales en el lugar de la inyección, como dolor, enrojecimiento, hinchazón, etc., y efectos sistémicos como fatiga, dolor de cabeza, dolor muscular o articular. Más infrecuentemente se pueden desarrollar cuadros linfadenopáticos sospechosos clínicamente de proceso linfoproliferativo. Presentamos el caso de una mujer de 30 años que desarrolló linfadenopatía axilar izquierda tras la vacunación contra la COVID-19 con hallazgos histopatológicos de linfadenopatía necrotizante de tipo Kikuchi y resolución espontánea. Hasta el momento se han publicado 7 casos con descripción clinicopatológica completa en la literatura y notificado 14 casos en la Red Europea de Farmacovigilancia en relación con la vacunación. Es importante tener en cuenta esta entidad en linfadenopatías sospechosas de procesos linfoproliferativos en este contexto, para evitar un tratamiento innecesario. (AU)


Assuntos
Humanos , Feminino , Adulto , Infecções por Coronavirus/epidemiologia , Vacinação em Massa/efeitos adversos , Linfadenite Histiocítica Necrosante
6.
Rev. esp. patol ; 57(1): 42-47, ene.-mar. 2024. ilus, tab
Artigo em Inglês | IBECS | ID: ibc-EMG-539

RESUMO

Subsequent to mass vaccination programs against COVID-19, diverse side effects have been described, both at the injection site, such as pain, redness and swelling, and systemic effects such as fatigue, headache, muscle or joint pain. On rare occasions, a lymphadenopathic syndrome may develop, raising the clinical suspicion of a lymphoproliferative disorder. We present the case of a 30-year-old woman who developed self-limiting left axillary lymphadenopathy following COVID-19 vaccination. To date, only seven similar cases with a complete clinicopathological description have been published, and fourteen cases have been notified to the European adverse events databases (Eudravigilance) in relationship with vaccination against COVID-19. It is important to be aware of this potential complication when a lymphadenopathic syndrome develops following vaccination, to avoid unnecessary treatment. (AU)


Tras la vacunación masiva frente a la COVID-19 se han comenzado a describir diversos efectos adversos incluyendo efectos locales en el lugar de la inyección, como dolor, enrojecimiento, hinchazón, etc., y efectos sistémicos como fatiga, dolor de cabeza, dolor muscular o articular. Más infrecuentemente se pueden desarrollar cuadros linfadenopáticos sospechosos clínicamente de proceso linfoproliferativo. Presentamos el caso de una mujer de 30 años que desarrolló linfadenopatía axilar izquierda tras la vacunación contra la COVID-19 con hallazgos histopatológicos de linfadenopatía necrotizante de tipo Kikuchi y resolución espontánea. Hasta el momento se han publicado 7 casos con descripción clinicopatológica completa en la literatura y notificado 14 casos en la Red Europea de Farmacovigilancia en relación con la vacunación. Es importante tener en cuenta esta entidad en linfadenopatías sospechosas de procesos linfoproliferativos en este contexto, para evitar un tratamiento innecesario. (AU)


Assuntos
Humanos , Feminino , Adulto , Infecções por Coronavirus/epidemiologia , Vacinação em Massa/efeitos adversos , Linfadenite Histiocítica Necrosante
7.
Science ; 383(6686): 939-940, 2024 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-38422136

RESUMO

A dramatic shortage of the oral vaccine may ease in the years ahead as more companies enter the market.


Assuntos
Vacinas contra Cólera , Cólera , Vacinação em Massa , Vacinas contra Cólera/provisão & distribuição , Administração Oral , Cólera/prevenção & controle , Saúde Global
8.
Sci Rep ; 14(1): 707, 2024 01 06.
Artigo em Inglês | MEDLINE | ID: mdl-38184669

RESUMO

As COVID-19 vaccines became widely available worldwide, many countries implemented vaccination certification, also known as a "green pass", to promote and expedite vaccination on containing virus spread from the latter half of 2021. This policy allowed those vaccinated to have more freedom in public activities compared to more constraints on the unvaccinated in addition to existing non-pharmaceutical interventions (NPIs). Accordingly, the vaccination certification also induced heterogeneous behaviors of unvaccinated and vaccinated groups. This makes it essential yet challenging to model the behavioral impact of vaccination certification on the two groups and the transmission dynamics of COVID-19 within and between the groups. Very limited quantitative work is available for addressing these purposes. Here we propose an extended epidemiological model SEIQRD[Formula: see text] to effectively distinguish the behavioral impact of vaccination certification on unvaccinated and vaccinated groups through incorporating two contrastive transmission chains. SEIQRD[Formula: see text] also quantifies the impact of the green pass policy. With the resurgence of COVID-19 in Greece, Austria, and Israel in 2021, our simulation results indicate that their implementation of vaccination certification brought about more than a 14-fold decrease in the total number of infections and deaths as compared to a scenario with no such a policy. Additionally, a green pass policy may offer a reasonable practical solution to strike the balance between public health and individual's freedom during the pandemic.


Assuntos
COVID-19 , Vacinação em Massa , Humanos , Vacinas contra COVID-19 , COVID-19/epidemiologia , COVID-19/prevenção & controle , Vacinação , Certificação
9.
Washington, D.C.; OPAS; 2024.
em Português | PAHO-IRIS | ID: phr-59513

RESUMO

A Região das Américas está recuperando suas taxas de cobertura de imunização para a maioria dos antígenos. Em 2022, a taxa de cobertura para a terceira dose da vacina contra difteria, tétano e coqueluche (DTP3) foi de 90% - acima dos 86% em 2021. No geral, 1,3 milhão de crianças com menos de 1 ano de idade continuam sem vacinação, em comparação com 1,9 milhão em 2021. Em 2002, os casos de dengue ultrapassaram 1 milhão, enquanto mais de 2 milhões foram registrados em 2013 e mais de 3 milhões em 2019. Embora a taxa regional de fatalidade de casos de dengue permaneça abaixo de 0,05%, o aumento da transmissão está prejudicando os esforços dos países para a recuperação social e econômica. Em setembro de 2023, o Grupo Consultivo Estratégico de Especialistas (SAGE) em Imunização da Organização Mundial da Saúde (OMS) recomendou o uso da série de duas doses da vacina contra a dengue TAK-003, produzida pela Takeda, para crianças de 6 a 16 anos de idade que vivem em ambientes com alta carga da doença da dengue e alta intensidade de transmissão. Durante essa XI reunião do Grupo Técnico Consultivo (TAG), a Secretaria da Organização Pan-Americana da Saúde (OPAS) solicitou aos membros do TAG que considerassem as evidências sobre a segurança e a eficácia dessa vacina e propusessem recomendações para seu uso nas Américas. Além disso, o vírus sincicial respiratório (VSR) é motivo de grande preocupação nas Américas. Os dados informados pelos Estados Membros à rede de vigilância respiratória integrada SARInet Plus da OPAS indicam que o VSR contribui significativamente para a carga de doenças respiratórias na Região. Por faixa etária, os casos e hospitalizações associados ao RSV foram registrados principalmente em bebês com menos de 2 anos de idade. Nos últimos meses, tanto a Food and Drug Administration (FDA) dos EUA quanto a European Medicines Agency (EMA) aprovaram a vacina RSVpreF Abrysvo produzida pela Pfizer para mulheres grávidas, com o objetivo de reduzir a incidência de RSV entre recém-nascidos com menos de 6 meses. Mais uma vez, os membros do GTA foram chamados a fornecer suas recomendações à OPAS sobre o uso dessa vacina nas Américas.


Assuntos
Vacinação , Vacinação em Massa , Vacinas contra Dengue , Infecções por Vírus Respiratório Sincicial , Acesso a Medicamentos Essenciais e Tecnologias em Saúde , Poliomielite
10.
Front Public Health ; 11: 1290350, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-38045968

RESUMO

Background: The rapid global spread of severe acute respiratory syndrome coronavirus (SARS-CoV-2) was met with the rollout of vaccination campaigns at mass vaccination centers. The Palazzo delle Scintille, Milan, was designated by the Lombardy regional administration as a vaccination site with the target of processing about 9,000 users daily. Methods: For this observational study, we compared data on vaccinations delivered at the Palazzo delle Scintille with coronavirus disease (COVID-19)-related regional data. Results: Between 25 April 2021 and 28 February 2023, a total of 1,885,822 COVID-19 doses were administered; the mean hourly rate was 289 (247.2), the mean daily rate was 3185.5 (3104.5), the mean user age was 49.5 years (10.7). The Comirnaty vaccine (Pfizer-BioNTech) was most often given (1,072,030/1,885,822; 56.8%). Between 4 December 2021 and 15 January 2022, the daily dose rate was above the maximum daily capacity set by the regional administration. Conclusion: The trend for daily dose rates administered at the Palazzo delle Scintille center was in line with COVID-19-related regional data. The center played a major role in the regional mass vaccination campaign.


Assuntos
COVID-19 , Vacinação em Massa , Humanos , Pessoa de Meia-Idade , COVID-19/epidemiologia , COVID-19/prevenção & controle , Itália/epidemiologia , SARS-CoV-2 , Vacinação , Adulto
11.
Ann Ist Super Sanita ; 59(4): 247-250, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-38088390

RESUMO

In recent times, especially as a result of the experience gained worldwide with the COVID19 pandemic vaccination campaigns, the personalization of vaccination strategies is becoming increasingly important. This does not yet mean bringing precision medicine and genomics approaches into immunization campaigns, but where there is more than one vaccine against the same disease, there is a need to identify criteria for personalizing vaccination.Vaccination strategies based on prescription appropriateness - whenever is possible - can lead to more effective immune response, reduced rates of adverse events, increased public confidence in vaccination and higher vaccination coverage, contributing to a decrease of morbidity and mortality related to preventable diseases.


Assuntos
COVID-19 , Vacinas , Humanos , Vacinação em Massa , Vacinologia , COVID-19/prevenção & controle , Vacinação , Vacinas/efeitos adversos , Programas de Imunização
12.
BMC Infect Dis ; 23(1): 748, 2023 Oct 31.
Artigo em Inglês | MEDLINE | ID: mdl-37907865

RESUMO

BACKGROUND: Many countries, including high-income nations, struggled to control epidemic waves caused by the Omicron variant (B.1.1.529), which had an antigenically distinct evolution. Evaluating the direct and indirect effects of vaccination during the Omicron waves is essential to assess virus control policies. The present study assessed the population impacts of a vaccination program during the sixth wave caused by BA.1 and BA.2 from January to May 2022, in Tokyo. METHODS: We analyzed the primary series and booster vaccination coverages and the confirmed cases stratified by vaccination history. We estimated the number of COVID-19 cases that were directly and indirectly prevented by vaccination. To estimate the direct impact, we used a statistical model that compared risks between unvaccinated and vaccinated individuals. A transmission model employing the renewal process was devised to quantify the total effect, given as the sum of the direct and indirect effects. RESULTS: Assuming that the reporting coverage of cases was 25%, mass vaccination programs, including primary and booster immunizations, directly averted 640,000 COVID-19 cases (95% confidence interval: 624-655). Furthermore, these programs directly and indirectly prevented 8.5 million infections (95% confidence interval: 8.4-8.6). Hypothetical scenarios indicated that we could have expected a 19% or 7% relative reduction in the number of infections, respectively, compared with the observed number of infections, if the booster coverage had been equivalent to that of the second dose or if coverage among people aged 10-49 years had been 10% higher. If the third dose coverage was smaller and comparable to that of the fourth dose, the total number of infections would have increased by 52% compared with the observed number of infections. CONCLUSIONS: The population benefit of vaccination via direct and indirect effects was substantial, with an estimated 65% reduction in the number of SARS-CoV-2 infections compared with counterfactual (without vaccination) in Tokyo during the sixth wave caused by BA.1 and BA.2.


Assuntos
Vacinas contra COVID-19 , COVID-19 , Humanos , Tóquio/epidemiologia , COVID-19/epidemiologia , COVID-19/prevenção & controle , SARS-CoV-2 , Vacinação , Vacinação em Massa
13.
Front Public Health ; 11: 1271162, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37915810

RESUMO

The SARS CoV-2 (COVID-19) pandemic presented unprecedented challenges as communities attempted to respond to the administration of a novel vaccine that faced cold chain logistical requirements and vaccine hesitancy among many, as well as complicated phased rollout plans that changed frequently as availability of the vaccine waxed and waned. The COVID-19 pandemic also disproportionately affected communities of color and communities with barriers to accessing healthcare. In the setting of these difficulties, a program was created specifically to address inequity in vaccine administration with a focus on communities of color and linguistic diversity as well as those who had technological barriers to online sign-up processes common at mass vaccination sites. This effort, the Mobile Vaccine Equity Enhancement Program (MVeeP), delivered over 12,000 vaccines in 24 months through a reproducible set of practices that can inform equity-driven vaccine efforts in future pandemics.


Assuntos
COVID-19 , Vacinas , Humanos , Pandemias , Vacinação em Massa , Vacinação , COVID-19/prevenção & controle
14.
J Glob Health ; 13: 04136, 2023 Nov 17.
Artigo em Inglês | MEDLINE | ID: mdl-37971948

RESUMO

Background: Despite growing efforts to improve access to vaccination, millions of children, especially in developing countries, have not received a single dose of diphtheria, tetanus, and pertussis (DTP) vaccine. Consequently, they are often called zero-dose children (ZDC). With limited health resources, prioritising communities for rapid and mass zero-dose catch-up vaccination in missed communities to avert epidemic outbreaks is complicated by unreliable denominators used to compute vaccination coverages. Incorporating other indicators of access and utilisation of vaccination services can help with identifying and ranking missed communities based on the likelihood of finding ZDC. We described the process of generating a scoring method to rank health areas in Cameroon based on their likelihood of containing ZDC. Methods: We used geospatial analysis to compute and aggregate health area characteristics, including hard-to-reach (HTR) areas (defined as areas of settlement above a one- (for urban areas) or 15-kilometre radius (for rural areas) beyond a vaccinating health facility), amount of area covered by slums and new area settlement, and percentage of children unvaccinated for DTP-1. We attributed a weight based on the ability to limit accessibility or utilisation of vaccination services to each characteristic and computed the score as a weighted average of health area characteristics. The health area score ranged from 0 to 1, with higher scores representing a higher likelihood of containing ZDC. We stratified the analysis by rural and urban health areas. Results: We observed substantial district and regional variations in health area scores, with hotspots health areas (administrative level 4) observed in the Far North (0.83), North (0.81), Adamawa (0.80), East (0.75), and South West (0.67) regions. The Adamawa region had the highest percentage of health areas with the highest score (78%), followed by the East (50%), West (48%), and North (46%) regions. For most regions (Far North, South, South West, Littoral, West, and North West), DTP-1 contributed the most to the score. However, HTR settlement areas within a health area contributed substantially to the overall score in the East, North, and Adamawa regions. Conclusions: We found substantial variations in health area scores with hotspots in the Far North, North, Adamawa, East, and South West regions. Although DTP-1 could be used as an indicator to identify health areas with ZDC for most communities, HTR settlement area was a valuable indicator in ranking priority health areas in the East, North, and Adamawa regions, further emphasising the need to consider other indicators before prioritisation.


Assuntos
Vacina contra Difteria, Tétano e Coqueluche , Vacinação , Humanos , Criança , Lactente , Camarões/epidemiologia , Vacinação em Massa , Cobertura Vacinal
15.
Hum Vaccin Immunother ; 19(3): 2276619, 2023 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-38013426

RESUMO

Acute gastroenteritis (AGE) caused by rotavirus (RV) remains a public health issue in China. To accelerate the mass rotavirus vaccination, it is important to inform the policy maker, and the public of the economic burden caused by rotavirus infection. A meta-analysis was conducted applying standardized algorithms. Articles published before January 1, 2023, in English and Chinese were searched through PubMed, CNKI, and WanFang Data. Studies with cost analysis of RV AGE were included. A random-effects model was applied to synthesize the total cost of RV AGE from the societal perspective. A prospective survey aimed to measure the cost of RV AGE was conducted in 2021 and 2022 in Shaoxing city, Zhejiang province, that can represent the developed region. The cost data was applied as deviation indicator, in comparison with the pooled estimate generated from meta-analysis. Totally 286 articles were identified, and eventually 12 studies were included. The pooled total social cost of RV AGE was US$282.1 (95%CI: US$213.4-350.7). The pooled private cost of RV AGE was US$206.4 (95%CI: US$155.2-257.5). RV AGE hospitalized and RV AGE incurred in developed regions caused remarkable higher burden (US$631.2 [95%CI: US$512.6-749.8], and US$333.6 [95%CI: US$234.1-433.2] respectively), compared to RV AGE treated at outpatient, and incurred in less developed regions. Our study demonstrates that RV AGE causes a significant economic burden in China. Given the promising effectiveness and highly cost-effective, introduction of rotavirus vaccines in national immunization programs could substantially reduce the economic burden in China.


Assuntos
Gastroenterite , Infecções por Rotavirus , Vacinas contra Rotavirus , Humanos , Lactente , Análise Custo-Benefício , População do Leste Asiático , Gastroenterite/epidemiologia , Gastroenterite/prevenção & controle , Gastroenterite/virologia , Vacinação em Massa , Estudos Prospectivos , Rotavirus , Infecções por Rotavirus/epidemiologia , Infecções por Rotavirus/prevenção & controle , Pré-Escolar
16.
Epidemics ; 45: 100725, 2023 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-37935076

RESUMO

Peste des petits ruminants (PPR) is an acute infectious disease of small ruminants targeted for global eradication by 2030. The Global Strategy for Control and Eradication (GSCE) recommends mass vaccination targeting 70% coverage of small ruminant populations in PPR-endemic regions. These small ruminant populations are diverse with heterogeneous mixing patterns that may influence PPR virus (PPRV) transmission dynamics. This paper evaluates the impact of heterogeneous mixing on (i) PPRV transmission and (ii) the likelihood of different vaccination strategies achieving PPRV elimination, including the GSCE recommended strategy. We develop models simulating heterogeneous transmission between hosts, including a metapopulation model of PPRV transmission between villages in lowland Ethiopia fitted to serological data. Our results demonstrate that although heterogeneous mixing of small ruminant populations increases the instability of PPRV transmission-increasing the chance of fadeout in the absence of intervention-a vaccination coverage of 70% may be insufficient to achieve elimination if high-risk populations are not targeted. Transmission may persist despite very high vaccination coverage (>90% small ruminants) if vaccination is biased towards more accessible but lower-risk populations such as sedentary small ruminant flocks. These results highlight the importance of characterizing small ruminant mobility patterns and identifying high-risk populations for vaccination and support a move towards targeted, risk-based vaccination programmes in the next phase of the PPRV eradication programme. Our modelling approach also illustrates a general framework for incorporating heterogeneous mixing patterns into models of directly transmitted infectious diseases where detailed contact data are limited. This study improves understanding of PPRV transmission and elimination in heterogeneous small ruminant populations and should be used to inform and optimize the design of PPRV vaccination programmes.


Assuntos
Peste dos Pequenos Ruminantes , Vírus da Peste dos Pequenos Ruminantes , Animais , Peste dos Pequenos Ruminantes/epidemiologia , Peste dos Pequenos Ruminantes/prevenção & controle , Ruminantes , Vacinação/veterinária , Vacinação em Massa
17.
Rev. neurol. (Ed. impr.) ; 77(10): 229-239, 16 - 30 de Noviembre 2023. tab, graf
Artigo em Inglês, Espanhol | IBECS | ID: ibc-227592

RESUMO

Introducción La cefalea es un síntoma frecuente en la fase aguda de la enfermedad por coronavirus 2019 (COVID-19) y también uno de los efectos adversos más comunes tras la vacunación. En ambos casos, la fisiopatología de la cefalea parece estar relacionada con la respuesta inmunitaria del huésped y podría presentar similitudes. Nuestro objetivo fue comparar el fenotipo clínico y la frecuencia de los síntomas asociados y los síntomas de inicio en pacientes con cefalea relacionada con la COVID-19 y cefalea relacionada con la vacuna de la COVID-19. Sujetos y métodos Se realizó un estudio de casos y controles. Se incluyó a pacientes con infección confirmada por COVID-19 y receptores de la vacuna de la COVID-19 que experimentaron un nuevo inicio de cefalea. Se administró un cuestionario estandarizado que incluyó variables demográficas, antecedentes previos de cefaleas, síntomas asociados y variables relacionadas con la cefalea. Ambos grupos se emparejaron por edad, sexo y antecedentes previos de cefaleas. Se realizó un análisis de regresión multivariante. Resultados Un total de 238 pacientes cumplieron con los criterios de elegibilidad (143 pacientes con cefalea relacionada con la COVID-19 y 95 sujetos con cefalea relacionada con la vacuna de la COVID-19). Los pacientes con cefalea relacionada con la COVID-19 presentaron una mayor frecuencia de artralgia, diarrea, disnea, dolor torácico, expectoración, anosmia, mialgia, odinofagia, rinorrea, tos y disgeusia. Además, los pacientes con cefalea relacionada con la COVID-19 experimentaron una duración diaria más prolongada de la cefalea y describieron la cefalea como la peor que habían experimentado. Los pacientes con cefalea relacionada con la vacuna de la COVID-19 experimentaron con más frecuencia dolor en la región parietal, fonofobia y empeoramiento de la cefalea por movimientos de la cabeza o de los ojos. Conclusión ... (AU)


INTRODUCTION Headache is a frequent symptom at the acute phase of coronavirus disease 2019 (COVID-19) and also one of the most frequent adverse effects following vaccination. In both cases, headache pathophysiology seems linked to the host immune response and could have similarities. We aimed to compare the clinical phenotype and the frequency and associated onset symptoms in patients with COVID-19 related-headache and COVID-19 vaccine related-headache. SUBJECTS AND METHODS A case-control study was conducted. Patients with confirmed COVID-19 infection and COVID-19-vaccine recipients who experienced new-onset headache were included. A standardised questionnaire was administered, including demographic variables, prior history of headaches, associated symptoms and headache-related variables. Both groups were matched for age, sex, and prior history of headache. A multivariate regression analysis was performed. RESULTS A total of 238 patients fulfilled eligibility criteria (143 patients with COVID-19 related-headache and 95 subjects experiencing COVID-19 vaccine related-headache). Patients with COVID-19 related-headache exhibited a higher frequency of arthralgia, diarrhoea, dyspnoea, chest pain, expectoration, anosmia, myalgia, odynophagia, rhinorrhoea, cough, and dysgeusia. Further, patients with COVID-19 related-headache had a more prolonged daily duration of headache and described the headache as the worst headache ever experienced. Patients with COVID-19 vaccine-related headache, experienced more frequently pain in the parietal region, phonophobia, and worsening of the headache by head movements or eye movements. CONCLUSION. Headache caused by SARS-CoV-2 infection and COVID-19 vaccination related-headache have more similarities than differences, supporting a shared pathophysiology, and the activation of the innate immune response. The main differences were related to associated symptoms. (AU)


Assuntos
Humanos , Cefaleia/fisiopatologia , /epidemiologia , Vacinação em Massa/efeitos adversos , /imunologia , Imunidade , Viroses , /efeitos adversos
18.
Health Res Policy Syst ; 21(1): 102, 2023 Oct 03.
Artigo em Inglês | MEDLINE | ID: mdl-37784061

RESUMO

BACKGROUND: Vaccination plays a critical role during pandemics, and mass vaccination clinics are often an imperative public health measure. These clinics usually consist of multi-disciplinary teams, which can pose significant coordination challenges, yet also present an opportunity for collectively contributing towards mitigating the impact of infection within communities. This study explores the coordination dynamics of the Region of Waterloo's coronavirus disease of 2019 (COVID-19) mass vaccination clinics in Ontario, Canada, between July 2021 and April 2022. METHODS: This qualitative study included 16 purposively selected participants working in mass vaccination clinics. Participants were individually interviewed for 40-60 min. An inductive and iterative thematic analysis was undertaken, including open coding, grouping, labelling, regrouping and making sense of the themes. RESULTS: Three interrelated themes were created: (1) unpredictable work environment, which was comprised of changing clinic processes and the impact of clinic adjustments to the running of the clinics; (2) clinic cohesion challenges, which included staff role disparities, limited job preparation and clinic system silos; and (3) adaptable and supportive work environment, which was comprised of staff adaptability, dispositional flexibility and a supportive work environment. While the first two themes created a precarious situation in the clinics, the third countered it, leading to a largely successful clinic implementation. CONCLUSIONS: The rapid evolution and high transmissibility of COVID-19 in communities required a public health response that felt like flying and building a plane simultaneously - a seemingly impossible yet necessary task. However, an adaptable and supportive work environment was critical for establishing an atmosphere that can overcome challenges from a constantly changing pandemic and the guidance of public health officials. Such lessons gained from understanding the dynamic experiences in mass vaccination clinics are essential for improving the development and operation of future immunization campaigns.


Assuntos
COVID-19 , Vacinação em Massa , Humanos , Ontário , COVID-19/prevenção & controle , Vacinação , Saúde Pública
19.
Enferm. glob ; 22(72): 402-416, oct. 2023. ilus, tab
Artigo em Espanhol | IBECS | ID: ibc-225962

RESUMO

Introducción: Durante la pandemia de COVID-19, disminuyó el cumplimiento de la inmunización infantil en Indonesia. Objectivo: Determinar los factores independientes y la relación entre el efecto sinérgico del apoyo de los maridos y la distancia a los centros de vacunación sobre el cumplimiento de la vacunación infantil durante la pandemia. Materiales y Métodos: Un total de 506 madres en la provincia de Jambi, Indonesia, participaron en un estudio transversal desde Marzo hasta Mayo de 2021. Las asociaciones entre los factores se analizaron mediante regresión logística. A partir de las variables más contribuyentes, los investigadores hicieron variables ficticias (2x2) para investigar la asociación sinérgica sobre el cumplimiento de la vacunación infantil del apoyo del marido y la distancia a los centros de vacunación. Resultados: Entre las variables con correlaciones positivas con la vacunación infantil, el apoyo de los esposos y la menor distancia a los centros de vacunación tuvieron un efecto sinérgico en el cumplimiento de la vacunación (AOR IC del 95 % = 4,10 [2–8,41]). Los grupos que recibieron menos apoyo del esposo y la distancia <4 km, así como los grupos que recibieron el apoyo del esposo, pero la distancia > 4 km tuvieron menos cumplimiento (AOR IC del 95 % = 2,47 [1,22–4,97]; 2,83 [1,18–6,81]). Conclusiones: El apoyo familiar y la accesibilidad a la inmunización infantil deben aumentar durante las campañas de vacunación. (AU)


Introduction: During the COVID-19 pandemic, compliance with childhood immunization in Indonesia declined. Objective: To determine the independent factors and the relation between the synergistic effect of husbands’ support and distance to vaccination centres on compliance with childhood immunization during the pandemic. Material and Methods: A total of 506 mothers in Jambi Province, Indonesia, participated in a cross-sectional study from March until May 2021. The associations between the factors were analysed using logistic regression. From the most contributing variables, the researchers made dummy variables (2x2) to investigate the synergistic association on compliance with childhood immunization of husband support and the distance to vaccination centres. Results: Among the variables with positive correlations to childhood vaccination, supportive husbands and less distance to vaccination centres had a synergistic effect on compliance with immunization (AOR 95% CI = 4.10 [2–8.41]). Groups that was less supportive from husband and the distance <4km as well as the groups was husband’s support but the distance >4km had less compliance (AOR 95% CI = 2.47 [1.22–4.97]; 2.83 [1.18–6.81]). Conclusions: Family support and accessibility to childhood immunization should be increased during vaccination campaigns. (AU)


Assuntos
Humanos , Pandemias , Infecções por Coronavirus/epidemiologia , Infecções por Coronavirus/imunologia , Infecções por Coronavirus/tratamento farmacológico , Vacinação em Massa , Indonésia , Coronavírus Relacionado à Síndrome Respiratória Aguda Grave , Inquéritos e Questionários , Estudos Transversais
20.
Nefrología (Madrid) ; 43(5)sep.-oct. 2023. tab, ilus
Artigo em Espanhol | IBECS | ID: ibc-224866

RESUMO

La infección por el SARS-CoV-2 (COVID-19) ha supuesto un importante impacto en la actividad trasplantadora en nuestro país. Era esperable que la mortalidad y el riesgo de complicaciones asociadas a la COVID-19 en el receptor de trasplante renal (TR) fueran mayores debido a su condición de inmunosupresión y a las frecuentes comorbilidades asociadas. Desde el inicio de la pandemia en marzo del 2020 hemos mejorado rápidamente nuestro conocimiento acerca de la epidemiología, características clínicas y manejo de la COVID-19 postrasplante, redundando en un mejor pronóstico para nuestros pacientes. Las unidades de TR han sabido adaptar sus programas a esta nueva realidad, normalizándose la actividad tanto de donación como de trasplante en nuestro país. Este manuscrito presenta una propuesta de actualización de las recomendaciones generales para la prevención y el tratamiento de la infección en esta población tan vulnerable como son los receptores de un trasplante renal. (AU)


SARS-CoV-2 infection (COVID-19) has had a significant impact on transplant activity in our country. Mortality and the risk of complications associated with COVID-19 in kidney transplant (KT) recipients were expected to be higher due to their immunosuppressed condition and the frequent associated comorbidities. Since the beginning of the pandemic in March 2020 we have rapidly improved our knowledge about the epidemiology, clinical features and management of COVID-19 post-transplant, resulting in a better prognosis for our patients. KT units have been able to adapt their programs to this new reality, normalizing both donation and transplantation activity in our country. This manuscript presents a proposal to update the general recommendations for the prevention and treatment of infection in this highly vulnerable population such as KT. (AU)


Assuntos
Humanos , Transplante de Rim , Pandemias , Infecções por Coronavirus/epidemiologia , Infecções por Coronavirus/prevenção & controle , Infecções por Coronavirus/complicações , Infecções por Coronavirus/tratamento farmacológico , Vacinação em Massa , Coronavírus Relacionado à Síndrome Respiratória Aguda Grave
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...